Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Gains from Sales and Divestitures (2020 - 2025)

Historic Gains from Sales and Divestitures for Adma Biologics (ADMA) over the last 6 years, with Q3 2025 value amounting to $1.8 million.

  • Adma Biologics' Gains from Sales and Divestitures rose 815.13% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 815.13%. This contributed to the annual value of $1.9 million for FY2024, which is 5727.8% up from last year.
  • Adma Biologics' Gains from Sales and Divestitures amounted to $1.8 million in Q3 2025, which was up 815.13% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Gains from Sales and Divestitures registered a high of $2.7 million during Q4 2022, and its lowest value of $87750.0 during Q2 2021.
  • Moreover, its 5-year median value for Gains from Sales and Divestitures was $1.2 million (2023), whereas its average is $1.2 million.
  • In the last 5 years, Adma Biologics' Gains from Sales and Divestitures surged by 284060.59% in 2022 and then plummeted by 5602.26% in 2023.
  • Over the past 5 years, Adma Biologics' Gains from Sales and Divestitures (Quarter) stood at $92750.0 in 2021, then skyrocketed by 2840.61% to $2.7 million in 2022, then tumbled by 56.02% to $1.2 million in 2023, then soared by 57.28% to $1.9 million in 2024, then decreased by 2.47% to $1.8 million in 2025.
  • Its last three reported values are $1.8 million in Q3 2025, $1.6 million for Q2 2025, and $1.5 million during Q1 2025.